Program
moxidectin
Also written as “Moxidectin” and “Moxidectin 2 MG Oral Tablet”.
Its studies are mostly in Infections · Blepharitis · Onchocerciasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 40 open or running | phase 2since Dec 17, 2009 | Aug 15, 2008 | none ahead |
| Eye Research Foundation | 10 open or running | phase 4since Jan 22, 2025 | Jan 22, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2008First study: phase 1 study in InfectionsNew to PfizerPfizer · NCT00736697 · 54 enrolled · France
- Sep 11, 2008Phase 1 study in InfectionsPfizer · NCT00751764 · 12 enrolled · United Kingdom
- Mar 4, 2009Phase 1 study in HealthyPfizer · NCT00856362 · 38 enrolled · Germany
- Dec 17, 2009Phase 2 study in OnchocerciasisPfizer · NCT01035619
- Jan 22, 2025Eye Research Foundation's first study: phase 4 study in BlepharitisNew to Eye Research FoundationEye Research Foundation · NCT06795165 · 24 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06795165Blepharitis · United States | 4 | Completed | Eye Research Foundation | Apr 28, 2025 | 24 |
| NCT01035619Onchocerciasis | 2 | Withdrawn | Pfizer | Apr 2011 | 0 |
| NCT00856362Healthy · Germany | 1 | Completed | Pfizer | Sep 2009 | 38 |
| NCT00751764Infections · United Kingdom | 1 | Completed | Pfizer | Sep 2009 | 12 |
| NCT00736697Infections · France | 1 | Completed | Pfizer | May 2009 | 54 |
How it is read
Names in the registry
- “moxidectin”, 2 entries
- “Moxidectin”, 2 entries
- “Moxidectin 2 MG Oral Tablet”, 1 entry
Conditions, from the studies’ own filings
- Infections, 2 studies
- Blepharitis, 1 study
- Onchocerciasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.